Good morning. Elizabeth Cooney here, taking the wheel from Ed Silverman today as we ponder a long weekend in observance of Labor Day this side of the pond, as Ed would say. Hope you can take a breather of some kind soon: Walk your dog, bike-share to a different borough, climb a new mountain. But stay safe and don’t forget your mask. Now let’s plow into the news of the day. …

Moncef Slaoui, the scientific leader of Operation Warp Speed, will quit his role in the Trump administration’s effort to develop a Covid-19 vaccine if he’s pressured to rush an unsafe or ineffective vaccine, he told Science. “I would immediately resign if there is undue interference in this process,” he said. He also told NPR an October vaccine is “extremely unlikely.” Slaoui has been dogged by controversy over his financial holdings in companies working on Covid-19 vaccines: He was on the board of Moderna (MRNA) and has since stepped down, but he retains his GlaxoSmithKline (GSK) stock.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy